ATRIP

ATR-interacting protein (ATM and Rad3-related

18,199 patent compounds predicted against ATRIP, 9,783 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2077611	0.56	18/20
SCHEMBL2080180	0.56	18/20
SCHEMBL2369755	0.47	16/20
SCHEMBL2369762	0.47	16/20
SCHEMBL2079418	0.58	15/20
SCHEMBL2078868	0.56	15/20
SCHEMBL796862	0.55	15/20
SCHEMBL796636	0.50	15/20
SCHEMBL2369782	0.47	13/20
SCHEMBL2369785	0.47	13/20
SCHEMBL2369424	0.52	12/20
SCHEMBL2369429	0.52	12/20
SCHEMBL3091820	0.53	11/20
SCHEMBL3080008	0.51	11/20
SCHEMBL738140	0.49	11/20
SCHEMBL2487507	0.49	11/20
SCHEMBL2487510	0.49	11/20
SCHEMBL3077782	0.47	11/20
SCHEMBL3588712	0.46	11/20
SCHEMBL2493212	0.45	11/20

Germline variants in ATRIP on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full ATRIP gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to ATRIP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	PHASE2	COMPLETED
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors	PHASE2	COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
AZD6738 for Patients With Progressive MDS or CMML	PHASE1	ACTIVE_NOT_RECRUITING
M6620 Plus Standard Treatment in Oesophageal and Other Cancer	PHASE1	COMPLETED
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ATRIP binder may also engage these)

Protein	Name	Similarity
Q9N077	—	1.000	Q9N077 →
Q3U1D0	—	0.997	Q3U1D0 →
Q8BMG1	—	0.995	Q8BMG1 →
Q3UJB9	—	0.994	Q3UJB9 →
Q7Z2Z1	—	0.993	Q7Z2Z1 →
Q9Y6A5	—	0.992	Q9Y6A5 →
O88480	—	0.992	O88480 →
Q6P2H3	—	0.992	Q6P2H3 →
Q8TF30	—	0.992	Q8TF30 →
Q3SYW0	—	0.991	Q3SYW0 →
Q80TQ5	—	0.991	Q80TQ5 →
Q8IWE5	—	0.991	Q8IWE5 →
Q15345	—	0.990	Q15345 →
O75800	—	0.990	O75800 →
Q6ZS81	—	0.990	Q6ZS81 →
E1U8D0	—	0.990	E1U8D0 →
Q9EQR6	—	0.990	Q9EQR6 →
Q8VC34	—	0.989	Q8VC34 →
Q3U6Q4	—	0.989	Q3U6Q4 →
Q0KK56	—	0.989	Q0KK56 →
Q5RAJ5	—	0.989	Q5RAJ5 →
Q92543	—	0.989	Q92543 →
Q3UHQ6	—	0.989	Q3UHQ6 →
Q96C34	—	0.989	Q96C34 →
Q58CQ0	—	0.989	Q58CQ0 →
Q569K6	—	0.989	Q569K6 →
Q5SZL2	—	0.989	Q5SZL2 →
B1A193	—	0.988	B1A193 →
Q8BQ33	—	0.988	Q8BQ33 →
Q6P1H6	—	0.988	Q6P1H6 →